5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

NGL Fine-Chem Ltd.

•
nglfinechem.comBSE: 524774NSE: NGLFINE
Market Cap₹ 1,681 Cr.
Current Price
High / Low₹ 3,602 / 1,271
Stock P/E29.4
Book Value₹ 563
Price to Book3.89
Dividend Yield0.06 %
ROCE16.9 %
ROE15.7 %
Face Value₹ 5

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 99.1% YoY, showing strong momentum
  • Company has consistently been profitable over the last 5 years
  • Company comfortably covers its interest (13.4x coverage)
  • Working capital cycle has improved - days down from 114 to 92
  • Company has a consistent dividend-paying track record
  • Company maintains a comfortable, low leverage position

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • Free cash flow has been persistently negative
  • Total debt has risen sharply - up 58.5% year on year
  • Company has delivered a poor profit growth of -3.2% over past five years
  • Though reporting repeated profits, the company pays out little dividend (2.2%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1864.0036.98447236.040.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9405.0085.36249673.200.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4928.4085.95187460.490.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1118.0024.71111520.930.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1380.0033.08111484.470.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1936.0095.67104604.450.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1669.0025.8796030.570.241032.0325.229150.3517.4412.7620.54
8.DRREDDY1140.8029.5595220.280.70435.60-69.108099.80-5.2113.7510.63
9.LUPIN2075.0017.1694882.670.871416.9816.018276.8934.2828.8629.59
10.MANKIND2246.0045.4292769.930.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2417.0037.9468213.700.10482.83927.884018.4831.3520.3520.03
12.NGLFINE2720.2529.381680.580.0618.4099.08139.1633.5716.8816.73
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
71808810091938995104120128149139
616674848182848993103105128122
Operating Profit10141416912561117222117
OPM %13.88%17.42%15.77%15.86%10.30%12.36%5.72%6.65%10.54%14.27%17.50%14.35%12.25%
334465-0-162527
Interest0000001111111
Depreciation3333333345555
Profit before Tax101414161213111213211824
Tax %15.67%24.82%30.01%23.43%21.80%26.41%-0.79%49.06%21.96%25.77%24.09%24.31%24.84%
Net Profit000091011910161318
13.7716.9616.2419.9514.9215.882.070.8814.9615.5825.4021.8329.78

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
153152258318278339368501536
121132178249243285333428458
Operating Profit322080683554357378
OPM %21.08%13.03%31.05%21.48%12.57%15.87%9.45%14.64%14.53%
4381161491517
Interest332222354
Depreciation688101112122021
Profit before Tax281278672754286376
Tax %26.99%30.96%26.90%25.08%25.09%24.07%23.78%24.05%24.67%
Net Profit20857502041214857
EPS0.0013.4991.8180.7733.1866.6334.1977.90—
Dividend Payout %5.37%13.32%1.91%2.17%5.30%2.63%5.12%2.25%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
14%
3 Years:
22%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
-3%
3 Years:
33%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
11%
1 Year:
86%

RETURN ON EQUITY

10 Years:
—
5 Years:
16%
3 Years:
14%
Last Year:
16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Aug 18

₹ 0.35

Rs.1.7500 per share(35%)Final Dividend

2025

Aug 12

₹ 0.35

Rs.1.7500 per share(35%)Final Dividend

2024

Aug 16

₹ 0.35

Rs.1.7500 per share(35%)Final Dividend

2023

Aug 18

₹ 0.35

Rs.1.7500 per share(35%)Final Dividend

2022

Jun 22

₹ 0.35

Rs.1.7500 per share(35%)Final Dividend

2021

Aug 12

₹ 0.35

Rs.1.7500 per share(35%)Final Dividend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital33333333
8996151200219260279326
24231127313375112
Trade Payables1621303725495265
171112109113255
Total Liabilities149154207277287356442560
616864898886143164
Capital Work in Progress0012626465095
911292939546039
1928385627435170
000009083131
Cash & Bank335113255
5844599693365156
Total Assets149154207277287356442560

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1624483142203243
Cash from Investing-10-20-25-14-27-27-70-71
Cash from Financing0-1-1-1-1-13730
-1-02-17-702

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
72.7472.7472.7472.7472.7472.7472.7472.7472.49
0.030.020.040.000.000.000.000.030.05
0.000.000.000.000.000.000.000.000.02
Government0.000.000.000.000.000.000.000.000.00
27.2327.2527.2227.2627.2627.2627.2627.2427.43

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-10 - NGL Fine-Chem Limited has informed the Exchange about Schedule of meet

2026-08-27
Shareholders meeting

2026-08-27 - NGL Fine-Chem Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 25, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-25
Shareholders meeting

2026-08-25 - NGL Fine-Chem Limited has informed the Exchange regarding Proceedings of undefined held on August 25, 2026

2026-08-20
Corrigendum

2026-08-20 - NGL Fine-Chem Limited has informed the Exchange regarding Corrigendum to the 45th Annual Report for the Financial Year 2025-2026

2026-08-17
Investor Presentation

2026-08-17 - NGL Fine-Chem Limited has informed the Exchange about Investor Presentation

2026-08-14
Copy of Newspaper Publication

2026-08-14 - NGL Fine-Chem Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-12
Updates

2026-08-12 - NGL Fine-Chem Limited has informed the Exchange regarding 'Board comments on fines levied by the Exchanges'.

2026-08-12
Integrated Filing- Financial

2026-08-12 - Outcome of Board Meeting

2026-08-12
Outcome of Board Meeting

2026-08-12 - NGL Fine-Chem Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

News

Recent coverage and analyst commentary for NGLFINE

Loading news…

🤖

AI Stock Analyst

NGL Fine-Chem Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login